GALENA BIOPHARMA, INC. (NASDAQ:GALE) Files An 8-K Regulation FD Disclosure

On August 8, 2017 at 5:00 a.m. P.T./8:00 a.m. E.T., the Company will host a conference call with investors to discuss the Agreement and Plan of Merger and Reorganization between the Company and SELLAS Life Sciences Group Ltd as previously filed with the Securities and Exchange Commission today on a Current Report on Form 8-K. The discussion including slides will be made available to the public via conference call and webcast.

The slides from the presentation are being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 and Exhibit 99.1 to this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing

Reference is made to the Exhibit Index included after the page to this Current Report on Form8‑K.

Galena Biopharma, Inc. ExhibitEX-99.1 2 sellasgalenamergerslides.htm EXHIBIT 99.1 sellasgalenamergerslides Galena Biopharma and SELLAS Life Sciences to Combine AUGUST 8,…To view the full exhibit click here
About GALENA BIOPHARMA, INC. (NASDAQ:GALE)
Galena Biopharma, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company’s NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company’s therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient’s own immune system to seek out and attack any residual cancer cells.